Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Correction of hypokalemia,Prevention of hypokalemia in patients at risk,Intravenous source of calories (dextrose)
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
Potassium has no true elimination half-life as it is homeostatically regulated; the terminal half-life of a potassium load is approximately 8-12 hours in healthy individuals, but this is highly variable and dependent on renal function, aldosterone status, and body stores. In anuric patients, potassium clearance is minimal, and dangerous accumulation can occur within hours.
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Potassium is not metabolized; excreted primarily by kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Primarily renal; >90% of potassium is excreted by the kidneys, with approximately 10% lost in feces. In steady state, urinary potassium excretion matches dietary intake (typically 40-120 m Eq/day). Dextrose is completely metabolized; unchanged dextrose excretion is negligible (<1% renal) in normoglycemic individuals.
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
Potassium: negligible (<2%) protein binding; it is present as free ions. Dextrose: not protein bound.
Approximately 45-50% bound primarily to albumin.
Potassium: Vd ~0.5 L/kg (total body water); essentially distributes throughout the entire body water. Over 98% of total body potassium is intracellular; the Vd for administered potassium is larger than that for extracellular markers due to rapid cellular uptake. Dextrose distributes into total body water (Vd ~0.6 L/kg).
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Intravenous: 100% bioavailability. Not administered by other routes for potassium repletion due to poor tolerability and absorption (e.g., oral bioavailability of potassium chloride is 80-90%, but GI irritation limits use).
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
GFR <30 m L/min: avoid use unless documented hypokalemia; maximum infusion rate 5 m Eq/h. GFR 30-50 m L/min: reduce rate to 5-10 m Eq/h. GFR >50 m L/min: standard dosing.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
No dose adjustment required for Child-Pugh class A or B. Class C: use with caution, monitor potassium levels and infusion rate; reduce maximum rate to 5 m Eq/h.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
0.5-1 m Eq/kg/dose IV, infused at a rate not exceeding 0.5-1 m Eq/kg/h; maximum concentration 40 m Eq/L for peripheral infusion. Adjust based on serum potassium levels.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
Reduce initial infusion rate to 5 m Eq/h; monitor renal function and serum potassium closely due to age-related decline in GFR; maximum concentration 40 m Eq/L.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
Potassium chloride injections are concentrated and must be diluted before administration. Rapid infusion may cause fatal hyperkalemia.
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Risk of hyperkalemia, especially in renal impairment,Monitor serum potassium and ECG during administration,Do not administer undiluted,Use with caution in patients with cardiac disease, metabolic acidosis, or hypovolemia,Extravasation risk may cause tissue necrosis
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Hyperchloremia,Conditions exacerbated by fluid overload
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
No specific food interactions. However, dietary potassium intake should be monitored when on high-dose potassium supplementation to avoid hyperkalemia. Avoid consuming large amounts of potassium-rich foods (e.g., bananas, oranges, tomatoes) without consulting a healthcare professional.
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, maternal hyperkalemia or severe acidosis/fluid shifts may adversely affect fetal outcome. Trimester-specific risks not established.
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Potassium and dextrose are normal constituents of breast milk. Intravenous administration results in minimal changes to milk composition. M/P ratio not applicable. Considered compatible with breastfeeding.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
No specific dose adjustments required. However, pregnant women may have increased plasma volume and altered renal function; standard dosing based on electrolyte and fluid deficits. Monitor serum potassium and glucose closely to avoid hyperkalemia or hyperglycemia.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
Potassium chloride in dextrose 5% is an intravenous solution for correction of hypokalemia and provision of maintenance fluids. Monitor serum potassium, renal function, and ECG during infusion. Maximum infusion rate: 10-20 m Eq/hour with continuous cardiac monitoring. Avoid in severe hyperkalemia, renal failure with oliguria, or conditions with potassium retention. Use central line if concentration >60 m Eq/L. Do not administer undiluted. Incompatible with amphotericin B, cefepime, and others.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
This solution is given intravenously to replace potassium and provide hydration.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the infusion or adjust the rate on your own.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking potassium supplements or certain blood pressure medications.,Inform your provider if you feel tingling, muscle weakness, irregular heartbeat, or confusion.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.. The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, mater. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.